Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 130
Filter
1.
J Zoo Wildl Med ; 50(1): 219-224, 2019 03 01.
Article in English | MEDLINE | ID: mdl-31120681

ABSTRACT

Five adult tigers (Panthera tigris) presented with a range of clinical signs, including paresis (2/5), lameness (2/5), ataxia (3/5), anorexia (5/5), and lethargy (5/5). Each tiger demonstrated elevated plasma globulin levels (7.8-14.8 g/dl; [reference interval 2-5.1 g/dl]) on routine biochemistry, confirmed as a monoclonal gammopathy using protein electrophoresis. Serum gammaglobulin concentration ranged from 5 to 7.5 g/dl, or 45.1-63.4% of total protein concentration. Azotemia was present in three tigers. Diagnostics and management varied with the presenting signs but included magnetic resonance imaging, radiography, chemotherapy, supportive care, and euthanasia. In each case, necropsy revealed a neoplastic plasma cell proliferation in the bone marrow and one or more extramedullary sites. Lytic lesions in the thoraco-lumbar spine were found in three animals, and one lesion was associated with spinal cord compression. Splenomegaly was present in 4/5 cases. Histopathology confirmed a plasma cell neoplasm in each case, and immunohistochemistry staining with multiple myeloma oncogene 1 (MUM1) was positive in each case. CD20 staining was performed in two cases and was positive in one. CD3 staining was performed in the same two cases, and was negative in each. Based on the clinical, gross, microscopic, and immunohistochemical findings, myeloma was diagnosed in all five tigers.


Subject(s)
Hypergammaglobulinemia/veterinary , Multiple Myeloma/veterinary , Tigers , Animals , Female , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/therapy , Male , Multiple Myeloma/diagnosis , Multiple Myeloma/therapy
2.
Blood ; 132(13): 1379-1385, 2018 09 27.
Article in English | MEDLINE | ID: mdl-30104220

ABSTRACT

Plasma hyperviscosity is a rare complication of both monoclonal and polyclonal disorders associated with elevation of immunoglobulins. Asymptomatic patients with an elevation in the serum viscosity do not require plasma exchange, and the majority will have other indications for therapeutic intervention. For patients with hemorrhagic or central nervous system manifestations, plasma exchange is the therapy of choice and is relatively safe. Viscosity measurements are not required to initiate therapy if the index of suspicion is high and the clinical presentation is typical. However, patients should have a sample sent for confirmation of the diagnosis. Whole-blood hyperviscosity is seen in patients with extreme elevation of the red cell and white cell count. Phlebotomy of patients with primary and secondary elevation of the red cell count is a well-established therapy.


Subject(s)
Blood Component Removal/methods , Blood Viscosity , Plasma Exchange/methods , Cryoglobulinemia/blood , Cryoglobulinemia/complications , Cryoglobulinemia/therapy , Disease Management , Humans , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/complications , Hypergammaglobulinemia/therapy , Male , Middle Aged , Sjogren's Syndrome/blood , Sjogren's Syndrome/complications , Sjogren's Syndrome/therapy
4.
Presse Med ; 46(1): 107-116, 2017 Jan.
Article in French | MEDLINE | ID: mdl-26922994

ABSTRACT

Rosai-Dorfman sinusal histiocytosis is a benign histiocytic disorder presenting as large lymphadenopathies, mostly in the cervical area. Visceral involvement is not unusual. The diagnosis is based on histologic findings, showing intrasinusoidal histiocytic infiltration with pathognomonic emperipolesis features. Histiocytes display a normal activated phenotype. It probably represents a heterogeneous group of diseases with some common histopathologic findings. An association with immunologic abnormalities or auto-immune diseases, mostly auto-immunes cytopenias is possible. This is a criterion of poor prognosis. The evolution can sometimes be spontaneously favorable. Nonetheless, there is a risk of compression, due to the huge volume of tumoral masses, especially in case of orbital or epidural involvement. Therapeutic abstention is usually justified. Treatments are discussed in threatening forms, evolving forms or in case of poor prognosis factors. Treatment, when indicated, is not codified. Surgery, corticosteroids, immunosuppressive agents and/or alpha interferon can be used.


Subject(s)
Histiocytosis, Sinus/pathology , Lymphadenopathy/pathology , Diagnosis, Differential , Histiocytosis, Sinus/complications , Histiocytosis, Sinus/therapy , Humans , Hypergammaglobulinemia/complications , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/therapy , Lymphadenopathy/complications , Lymphadenopathy/therapy
5.
Bol. Asoc. Argent. Odontol. Niños ; 43(1): 19-27, abr.-ago. 2014. ilus, tab, graf
Article in Spanish | LILACS | ID: lil-761839

ABSTRACT

El síndrome de Hiper EgE (SHIE) es una rara inmunodeficiencia caracterizada por abscesos cutáneos, neumonías recurrentes, conformación de neumatoceles y elevados niveles de IgE en suero. Se ha reconocido la asociación de rasgos faciales, esqueléticos y dentales, pero su frecuencia es poco conocida. Objetivo: describir la epidemiología, presentación clínica, hallazgos de laboratorio y tratamiento de este síndrome desde el punto de vista médico y odontológico, con énfasis en las manifestaciones estomatológicas y dentales. Métodos. Métodos: realizamos una revisión científica sistemática de todos los reporte y series de casos de SHIE en las bases de datos Lilacs, Medline, SciELO y Biblioteca Cochrane, utilizando como descriptores DeCS/MeSH las palabras claves: hyper IgE AND immunodeficiency, hypereosinophilia, Job´s syndrome, hiperinmunoglobulinemia E. Resultados: revisamos 31 publicaciones con 328 pacientes. Los abscesos cutáneos se encontraron en 89 pior ciento de los casos, la neumonía en el 87 por ciento y la IgE sérica dio una mediana de 3.417 Ul/mL. Los rasgos faciales característicos estuvieron en el 69 por ciento, las alteraciones dentarias en 58 por ciento y la candidiasis oral fue reportada en 53 por ciento de los pacientes. Conclusión: el síndrome de IgE es un desorden multisistémico que afecta a la dentición, el esqueleto, el tejido conectivo y el sistema inmune. Por esto, el odontopediatra debe ser capaz de reconocer el fenotipo orofacial para mejorar la calidad del diagnóstico y brindar el abordaje terapéutico apropiado...


Subject(s)
Humans , Male , Female , Hypergammaglobulinemia/complications , Immunoglobulin E , Oral Manifestations , Tooth Abnormalities/etiology , Hypergammaglobulinemia/epidemiology , Hypergammaglobulinemia/therapy , Data Interpretation, Statistical , Job Syndrome/pathology , Hypergammaglobulinemia/blood
6.
Avian Dis ; 58(2): 326-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25055643

ABSTRACT

A 15-yr-old cockatiel (Nymphicus hollandicus) presented with decreased activity and appetite. A presumptive diagnosis of lymphoproliferative disease was made because of a monoclonal band observed on plasma protein electrophoresis. The owner declined further diagnostics or treatment, and the bird died 2 yr later. In a second case, a 4-yr-old blue and gold macaw (Ara ararauna) presented with lethargy and anorexia. Despite supportive treatment, the bird died 7 days later. Blood studies also demonstrated a monoclonal band on plasma protein electrophoresis. The histologic review of tissues from both birds found extensive neoplastic lymphoplasmocytic cells in the liver and supported a diagnosis of lymphosarcoma.


Subject(s)
Bird Diseases/diagnosis , Blood Protein Electrophoresis/methods , Lymphoma, Non-Hodgkin/veterinary , Parrots , Animals , Bird Diseases/therapy , Blood Protein Electrophoresis/veterinary , Fatal Outcome , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/therapy , Hypergammaglobulinemia/veterinary , Liver/pathology , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/therapy , Male
7.
Subcell Biochem ; 65: 609-42, 2012.
Article in English | MEDLINE | ID: mdl-23225018

ABSTRACT

The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.


Subject(s)
Amyloid/blood , Amyloidosis , Hypergammaglobulinemia , Immunoglobulin Light Chains/blood , Amyloidosis/blood , Amyloidosis/pathology , Amyloidosis/therapy , Animals , Hematopoietic Stem Cell Transplantation , Humans , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/pathology , Hypergammaglobulinemia/therapy
8.
Immunotherapy ; 4(11): 1121-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23194362

ABSTRACT

Interferon-γ receptor-1 (IFNγR1) deficiency is caused by mutations in the IFNγR1 gene and is characterized mainly by susceptibility to mycobacterial disease. Herein, we report an 8-month-old boy with complete recessive IFNγR1 deficiency, afflicted by recurrent mycobacterial diseases with Mycobacterium bovis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare and Mycobacterium fortuitum. Genetic analysis showed a homozygous mutation (106insT) in the IFNγR1 gene leading to complete IFNγR1 deficiency. In addition, he had atypical mycobacterial skin lesions caused by M. avium intracellulare and developed scrotal and lower limb lymphedema secondary to compression of large and fixed inguinal lymphadenopathies. Hematopoietic stem cell transplantation was performed from a matched unrelated donor at 5 years of age; however, he died at 9 months post-transplant. To our knowledge, the patient is the first case with IL-12/IFN-γ pathway defect and severe lymphedema. We have also reviewed and summarized the literature related with IFNγR1 deficiency.


Subject(s)
Granuloma/immunology , Hypergammaglobulinemia/immunology , Lymphedema/immunology , Mycobacterium avium-intracellulare Infection/immunology , Mycobacterium/immunology , Receptors, Interferon/genetics , Tuberculosis, Cutaneous/immunology , Child , Child, Preschool , Consanguinity , DNA Mutational Analysis , Fatal Outcome , Granuloma/genetics , Granuloma/therapy , Hematopoietic Stem Cell Transplantation , Humans , Hypergammaglobulinemia/genetics , Hypergammaglobulinemia/therapy , Infant , Lower Extremity/pathology , Lymphedema/genetics , Lymphedema/therapy , Male , Mycobacterium avium-intracellulare Infection/genetics , Mycobacterium avium-intracellulare Infection/therapy , Pedigree , Scrotum/pathology , Sequence Deletion/genetics , Tuberculosis, Cutaneous/genetics , Tuberculosis, Cutaneous/therapy , Interferon gamma Receptor
9.
Rev. clín. esp. (Ed. impr.) ; 211(10): 520-526, nov. 2011.
Article in Spanish | IBECS | ID: ibc-91262

ABSTRACT

El síndrome de la hipergammaglobulinemia IgE con infecciones recurrentes es una inmunodeficiencia primaria poco frecuente, que se caracteriza por niveles elevados de IgE, dermatitis eccematoide, infecciones recurrentes de piel y pulmón por Staphylococcus aureus, y formación de abscesos con escasos signos inflamatorios. También produce alteraciones dentarias, esqueléticas y del tejido conjuntivo. La forma clásica (tipo 1) está causada por mutaciones dominantes del gen de la proteína transductora de señal y activadora de la transcripción 3. Se ha descrito una forma incompleta (tipo 2) solo con las manifestaciones de la inmunodeficiencia, pero sin manifestaciones mesenquimales. Esta forma incompleta se debe a la mutación recesiva del gen de la tirosin-cinasa 2. Ambas mutaciones condicionan un déficit en la generación de células Th17 a partir de células T CD4+. Estos avances en el conocimiento genético e inmunológico del síndrome de hipergammaglobulinemia IgE han permitido la mejor comprensión de los fenómenos clínicos de la enfermedad(AU)


Hyper-IgE recurrent infection syndrome is an uncommon primary immunodeficiency characterized by high serum levels of total IgE, eczema-like dermatitis, recurrent skin abscesses and staphylococci pneumonias, which can produce abscesses with mild inflammatory signs. It also causes dental, musculoskeletal and connective tissue abnormalities. The classical (type 1) variation is caused by autosomal-dominant mutations in signal transducer and activator of transcription 3. An incomplete form (type 2) has been described with only the immunological manifestations, but without the mesenchymal manifestations, has been described. This incomplete form is caused by recessive mutations in the tyrosine kinase 2 gene. Both kinds of mutations produce deficient formation of Th17-cells. These advances in the genetic and immunologic knowledge of hyper-IgE recurrent infection syndrome have allowed a better clinical comprehension of the clinical phenomena of the disease(AU)


Subject(s)
Humans , Male , Middle Aged , Hypergammaglobulinemia/complications , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/therapy , Hereditary Autoinflammatory Diseases/complications , TYK2 Kinase/administration & dosage , TYK2 Kinase , Eczema/complications , Eczema/diagnosis , Diagnosis, Differential , Hypergammaglobulinemia/physiopathology , Th17 Cells/pathology , STAT Transcription Factors , STAT Transcription Factors/genetics
10.
Bol. Asoc. Argent. Odontol. Niños ; 39(1): 11-17, abr.-ago. 2010. ilus
Article in Spanish | LILACS | ID: lil-599092

ABSTRACT

El síndrome de Hiper IgE o hiperinmunoglobulinemia E por infección recurrente es una enfermedad rara, descripta inicialmente por JOb Buckey en 1966. Su diagnóstico se realiza a través de la tríada: *)eosinofilia y elevados niveles de IgE, *) eczema e infecciones recurrentes de piel y *) aparato respiratorio (pulmones). Tiene dos variantes: tipo 1 o autosómica y tipo 2 o autosómica recesiva. PUedepresentar facies características y alteraciones óseas y dentales. Son pacientes que requieren terapias prolongadas con antibióticos para evitar las infecciones respiratorias. La importancia de la atención odontológica radica en mantener una boca saludable para evitar focos sépticos que pongan en riesgo la vida del paciente.


Subject(s)
Humans , Child , Dental Care for Chronically Ill/methods , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/therapy , Immunoglobulin E/physiology , Job Syndrome/therapy , Oral Manifestations , Job Syndrome/pathology
11.
Ophthalmic Plast Reconstr Surg ; 26(2): 126-7, 2010.
Article in English | MEDLINE | ID: mdl-20305517

ABSTRACT

The authors report a case of orbital plasmacytoma in a 48-year-old man with known multiple myeloma. He presented with proptosis, diplopia, and decreased vision of the left eye for several weeks. He had been previously treated for IgA lambda multiple myeloma with chemotherapy, radiation, and autologous stem cell transplant. After a left orbitotomy, flow cytometry revealed a tumor rich in plasma cells expressing CD138 with equivocal lambda light chain expression. The patient underwent orbital radiation, with improvement of vision and disc edema OS. The patient is currently undergoing salvage chemotherapy for relapse of multiple myeloma. This is the third reported case of IgA myeloma involving the orbit.


Subject(s)
Hypergammaglobulinemia/pathology , Immunoglobulin A , Multiple Myeloma/pathology , Orbital Neoplasms/pathology , Plasmacytoma/pathology , Combined Modality Therapy , Flow Cytometry , Humans , Hypergammaglobulinemia/immunology , Hypergammaglobulinemia/therapy , Immunoglobulin lambda-Chains/immunology , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Myeloma/immunology , Multiple Myeloma/therapy , Orbital Neoplasms/immunology , Orbital Neoplasms/therapy , Plasma Cells/immunology , Plasma Cells/pathology , Plasmacytoma/immunology , Plasmacytoma/therapy , Proto-Oncogene Proteins c-bcl-2/metabolism , Syndecan-1/metabolism , Tomography, X-Ray Computed
13.
Am J Ophthalmol ; 145(6): 1002-1006, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18336788

ABSTRACT

PURPOSE: To determine the characteristics of patients with primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma associated with polyclonal hypergammaglobulinemia. DESIGN: Case series study. METHODS: Among 81 Japanese patients with primary ocular adnexal MALT lymphoma, seven patients (9%) were diagnosed with polyclonal hypergammaglobulinemia. Patient clinical data included a history of autoimmune disease and dissemination. Peripheral blood collected from all patients was analyzed for serum levels of rheumatoid factor, soluble interleukin-2 receptor (sIL-2R), and immunoglobulins at the time of diagnosis and after each treatment. RESULTS: Seven patients with polyclonal hypergammaglobulinemia had elevated serum levels of rheumatoid factor, sIL-2R, immunoglobulin G (IgG), and immunoglobulin E (IgE) at the time of diagnosis. One patient had Sjogren syndrome. Six patients (86%) had a dissemination of the MALT lymphoma or lymphadenopathy at the time of diagnosis. Histopathologic examination of the patients with lymphadenopathy revealed not only MALT lymphoma but also secondary follicles. None of the seven patients showed improvement in serum levels of IgG, rheumatoid factor, or sIL-2R in spite of complete regression of the ocular lesions after radiotherapy. After administration of cyclophosphamide/doxorubicin/vincristine/prednisone and/or rituximab to three patients, all three showed improved serum levels of IgG, rheumatoid factor, and sIL-2R. CONCLUSIONS: Patients with ocular adnexal MALT lymphoma and polyclonal hypergammaglobulinemia have elevated serum levels of rheumatoid factor, sIL-2R, and IgE, and high dissemination or lymphadenopathy. These unique characteristics may correlate with the systemic immunologic imbalances.


Subject(s)
Conjunctival Neoplasms/complications , Hypergammaglobulinemia/complications , Lacrimal Apparatus Diseases/complications , Lymphoma, B-Cell, Marginal Zone/complications , Orbital Neoplasms/complications , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Conjunctival Neoplasms/pathology , Conjunctival Neoplasms/therapy , Female , Humans , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/therapy , Immunoglobulin G/blood , Lacrimal Apparatus Diseases/pathology , Lacrimal Apparatus Diseases/therapy , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/therapy , Male , Middle Aged , Orbital Neoplasms/pathology , Orbital Neoplasms/therapy , Radiotherapy , Receptors, Interleukin-2/blood , Rheumatoid Factor/blood
14.
Invest Ophthalmol Vis Sci ; 49(3): 1157-60, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18326744

ABSTRACT

PURPOSE: Waldenström's macroglobulinemia (WM) is characterized by an overproduction of immunoglobulin M (IgM), which can lead to a hyperviscosity syndrome (HVS) and HVS-related retinopathy. Plasmapheresis is known to reduce serum viscosity (SV) and IgM levels. The purpose of this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal hemodynamic parameters in patients with WM. METHODS: Nine patients with HVS due to WM were studied. SV and plasma IgM levels were measured before and after plasmapheresis treatment. The patients were evaluated for HVS-related retinopathy, and hemodynamic changes in a major temporal retinal vein by laser Doppler, before and after plasmapheresis. RESULTS: Plasmapheresis resulted in significant reductions in serum IgM (46.5% +/- 18.0%, mean +/- SD; P = 0.0009) and SV (44.7% +/- 17.3%, P = 0.002). HVS-related retinopathy improved in all patients after plasmapheresis. After treatment, the venous diameter decreased in each patient by an average of 15.3% +/- 5.8% (P = 0.0001). A significant (P = 0.0004) 55.2% +/- 22.5% increase in retinal venous blood speed accompanied the decreases in diameter. There was no significant change in the retinal blood flow rate after treatment. The percentage decreases in SV in the patients were significantly correlated with the percentage decreases in venous blood column diameter (P = 0.031, R(2) = 0.51). CONCLUSIONS: HVS triggers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance. However, the retinal blood flow is not decreased as in CRVO, but remains at normal levels. Plasmapheresis is effective in reversing HVS-related retinopathy and in reducing abnormal venous dilatation.


Subject(s)
Blood Viscosity , Hypergammaglobulinemia/blood , Immunoglobulin M/blood , Plasmapheresis , Retinal Diseases/blood , Waldenstrom Macroglobulinemia/blood , Blood Flow Velocity , Female , Hemodynamics/physiology , Humans , Hypergammaglobulinemia/physiopathology , Hypergammaglobulinemia/therapy , Laser-Doppler Flowmetry , Male , Middle Aged , Retinal Diseases/physiopathology , Retinal Diseases/therapy , Retinal Vessels/physiopathology , Syndrome , Waldenstrom Macroglobulinemia/physiopathology , Waldenstrom Macroglobulinemia/therapy
15.
Nihon Rinsho ; 65(12): 2229-34, 2007 Dec.
Article in Japanese | MEDLINE | ID: mdl-18069265

ABSTRACT

Renal involvement is common in multiple myeloma. Although several types of renal disease are observed, most of them are considered to be specifically related to monoclonal immunoglobulin light chains. Myeloma cast nephropathy is the most frequent and sometimes associated with acute renal failure. AL amyloidosis and monoclonal immunoglobulin deposit disease are often presented as a nephrotic syndrome. In this review, we describe the pathogenesis and diagnosis of these three renal diseases. We also focus on the treatment of renal disease in multiple myeloma, in the view points of the chemotherapy to reduce M-protein and the prevention to reduce the risks of promoting renal injury.


Subject(s)
Kidney Diseases/etiology , Multiple Myeloma/complications , Amyloidosis/diagnosis , Amyloidosis/etiology , Amyloidosis/physiopathology , Amyloidosis/therapy , Biomarkers/analysis , Combined Modality Therapy , Dexamethasone/administration & dosage , Hematopoietic Stem Cell Transplantation , Humans , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/etiology , Hypergammaglobulinemia/physiopathology , Hypergammaglobulinemia/therapy , Immunoglobulin Light Chains , Kidney Diseases/diagnosis , Kidney Diseases/physiopathology , Kidney Diseases/therapy , Melphalan/administration & dosage , Myeloma Proteins/analysis , Plasma Exchange , Prednisolone/administration & dosage
16.
Blood ; 110(10): 3561-3, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17673601

ABSTRACT

Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.


Subject(s)
Amyloidosis/therapy , Hypergammaglobulinemia/therapy , Immunoglobulin Light Chains , Melphalan/administration & dosage , Stem Cell Transplantation , Adult , Aged , Amyloidosis/mortality , Combined Modality Therapy/mortality , Dose-Response Relationship, Drug , Follow-Up Studies , Humans , Hypergammaglobulinemia/mortality , Kaplan-Meier Estimate , Middle Aged , Survivors , Time Factors , Treatment Outcome
17.
J Inherit Metab Dis ; 29(6): 763, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17103011

ABSTRACT

Hyper-IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL-1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.


Subject(s)
Fever/therapy , Hypergammaglobulinemia/complications , Hypergammaglobulinemia/therapy , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Fever/etiology , Humans , Immunoglobulin D/chemistry , Inflammation , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...